knowledge
WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John Crowley as its new CEO, the organization announced Tuesday.
Crowley came to biotech when his children were diagnosed with a rare genetic neuromuscular disease. He started working at Bristol Myers Squibb, and started Novazyme, which was eventually successful in creating an enzyme replacement therapy for Pompe disease. He later started and worked for several different biotech companies, most recently with Amicus Therapeutics, which had a drug approved to treat the disease in September.
advertisement
The trade association’s board chair, Ted Love, served on the board of the company.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： As demand for Covid shots wanes, Moderna seeks its next success
